M

    MDxHealth SA ADR (MDXH)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $0.72
    -0.00 (-0.07%)

    Market Cap: $68.77M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    23%(5/22)
    Avg Surprise
    -53.77%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.09
    Range$-0.11 - $-0.06
    5 analysts
    EPS Revisions
    1
    0
    7d
    1
    4
    30d
    EPS Estimate Drift
    90d ago$-0.16-76.1%
    60d ago$-0.16-76.1%
    30d ago$-0.16-76.1%
    7d ago$-0.09+2.2%
    Current$-0.09
    Revenue Consensus
    $25M
    Range$23M - $25M
    6 analysts
    Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.02 - $-0.02
    1 analysts
    Revenue Consensus
    $23M
    Range$21M - $25M
    6 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.02---
    Sep 26EST
    		-$-0.09---
    Jun 26
    		$-0.18$-0.12-50.00%Miss-28.6%
    Mar 26
    		$-0.17$-0.15-13.33%Miss+10.5%
    Dec 25
    		$-0.17$-0.13-30.77%Miss-21.4%
    Sep 25
    		$-0.16$-0.11-45.45%Miss+60.0%
    Jun 25
    		$-0.14$-0.12-16.67%Miss+54.8%
    Mar 25
    		$-0.19$-0.13-46.15%Miss+38.7%
    Dec 24
    		$-0.14$-0.19+26.32%Beat+64.1%
    Sep 24
    		$-0.40$-0.25-60.00%Miss+0.0%
    Jun 24
    		$-0.31$-0.26-19.23%Miss-3.3%
    Mar 24
    		$-0.31$-0.30-3.33%Miss+38.0%
    Dec 23
    		$-0.39$-0.25-56.00%Miss+64.5%
    Sep 23
    		$-0.40$-0.19-110.53%Miss+20.0%
    Jun 23
    		$-0.30$-0.22-36.36%Miss+57.1%
    Mar 23
    		$-0.50$-0.40-25.00%Miss+0.0%
    Dec 22
    		$-1.10$-0.65-69.23%Miss-25.0%
    Sep 22
    		$-0.50$-0.53+5.66%Beat+88.9%
    Jun 22
    		$-0.70$-0.60-16.67%Miss-1066.7%
    Mar 22
    		$-0.50$-0.53+5.66%Beat-733.3%
    Dec 21
    		$-0.88$-0.47-87.23%Miss-961.5%
    Sep 21
    		$-4.50$-0.60-650.00%Miss-650.0%
    Mar 21
    		$-0.06$0.00N/AMiss+33.3%
    Dec 20
    		$-0.06$0.00N/AMiss+33.3%
    Sep 20
    		$-0.08$0.00N/AMiss+62.1%
    Jun 20
    		$-0.60N/A+62.50%Beat-174.5%
    Mar 20
    		$-0.09$0.00N/AMiss+25.0%
    Dec 19
    		$-0.09$0.00N/AMiss+25.0%
    Sep 19
    		$-0.22$0.00N/AMiss-49.4%
    Jun 19
    		$-0.22$0.00N/AMiss+72.7%
    Mar 19
    		$-0.12$0.00N/AMiss+11.1%
    Dec 18
    		$-0.12$0.00N/AMiss+11.1%
    Sep 18
    		$-0.15$0.00N/AMiss-12.1%
    Jun 18
    		$-0.80N/A+52.94%Beat-513.0%
    Mar 18
    		$-0.14$0.00N/AMiss-2800.0%
    Dec 17
    		$-0.14$0.00N/AMiss-2800.0%
    Sep 17
    		$-0.13$0.00N/AMiss-116.1%
    Jun 17
    		$-0.13$0.00N/AMiss-
    Mar 17
    		$0.01$0.00N/ABeat-
    Dec 16
    		$0.01$0.00N/ABeat-
    Sep 16
    		$-0.06$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-1.06EV/EBITDA17.57x
    Price/FCF418.96xFCF Yield0.24%
    Profitability
    Profit Margin-32.70%Operating Margin-18.70%
    ROE-2440.00%ROIC-29.66%
    Financial Health
    Debt/Equity-8.09xInterest Coverage-0.92x
    Current Ratio1.08xQuick Ratio0.94x
    Trading Statistics
    Beta-501440.84Avg Volume16.85M
    52-Week High$5.3352-Week Low$0.40

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.74
    SMA 20$0.63
    SMA 50$0.52
    SMA 200$2.15
    EMA 10$0.72
    EMA 20$0.66
    EMA 50$0.68
    EMA 200$1.69

    MACD

    Line: 0.07Signal: 0.06Hist: 0.00

    ADX

    ADX: 49.8+DI: 33.2-DI: 10.5

    Aroon & PSAR

    Aroon Up56.0
    Aroon Down12.0
    PSAR$1.07

    Bollinger Bands

    Upper Band$0.95
    Lower Band$0.32
    %B Position9945%(Upper)
    Band Width0.64

    RSI (14-Day)

    Neutral
    60.0

    Momentum Oscillators

    Stoch %K40.8
    Stoch %D43.6
    Williams %R-59.8
    ROC (10d)-15.8%
    Momentum-0.14
    CCI (20d)35.4
    MFI (14d)95.6

    Volatility Measures

    ATR (14d)$0.08(10.8%)
    StdDev (20d)0.16
    Hist Vol276.9%(High)

    Volume Flow

    VWAP$0.72
    OBV298.6M
    AD Line-73.8M
    CMF (20d)-0.166

    Volume Metrics

    Avg Vol (20d)17.7M
    Vol Ratio0.0x(Low)
    VWMA (20d)$0.80

    Pivot Points

    R3$0.82
    R2$0.79
    R1$0.75
    Pivot Point$0.72
    S1$0.68
    S2$0.65
    S3$0.61

    Advanced Oscillators

    TSI27.42
    Ultimate Osc45.9
    KST645.87

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$54.66M$54.66M$27.43M$26.61M$24.29M$48.06M$23.32M$41.99M$19.83M$38.75M$19.35M$31.45M
    Cost of Revenue$25.36M$25.36M$9.56M$9.04M$8.79M$18.26M$9.04M$16.64M$7.77M$13.52M$6.80M$12.74M
    Gross Profit$29.31M$29.31M$17.88M$17.57M$15.50M$29.79M$14.28M$25.35M$12.06M$25.22M$12.55M$18.70M
    Operating Expenses$40.88M$40.88M$20.52M$19.48M$20.09M$40.49M$20.37M$39.37M$18.67M$36.09M$17.11M$35.16M
    R&D$10.35M$10.35M$2.01M$2.57M$2.50M$5.49M$2.70M$5.07M$2.16M$1.02M$1.56M$2.20M
    SG&A$39.44M$39.44M$7.46M$6.24M$5.84M$11.60M$5.74M$11.20M$5.36M$40.02M$5.38M$10.89M
    Operating Income$-11,569,000$-11,569,000$-2,642,000$-1,916,000$-4,588,000$-10,700,000$-6,092,000$-14,022,000$-6,604,000$-10,867,000$-4,561,000$-16,460,000
    Interest Income$7.38M$127,000$502,000$420,000$692,000$694,000$197,000$0$1.37M$0$564,000$0
    Interest Expense$8.38M$8.38M$5.88M$6.29M$5.18M$7.14M$4.96M$4.66M$3.28M$10.46M$6.05M$2.99M
    Income Before Tax$-19,800,000$-19,800,000$-8,016,000$-7,788,000$-9,072,000$-17,648,000$-10,855,000$-20,039,000$-8,511,000$-20,764,000$-10,045,000$-22,335,000
    Income Tax Expense$-1,025,000$-1,025,000$-6,000$-416,000$137,000$382,000$334,000$0$1,000$1,000$1.90M$-3,078,000
    Net Income$-18,775,000$-18,775,000$-8,010,000$-7,372,000$-9,209,000$-18,030,000$-11,189,000$-20,039,000$-8,511,000$-20,765,000$-10,045,000$-22,335,000
    EBITDA$-6,893,000$-6,740,000$680,000$770,000$-1,649,000$-6,162,000$-3,747,000$-8,953,000$-3,333,000$-17,046,000$-2,132,000$-15,931,000
    EBIT$-11,569,000$-11,416,000$-2,140,000$-1,496,000$-3,896,000$-10,503,000$-5,895,000$-12,651,000$-5,233,000$-20,493,000$-3,997,000$-19,343,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about MDXH

    Government Contracts

    Gov Obligations (TTM)
    $875172
    Gov Obligations / Revenue
    0.8%
    Obligations YoY
    N/A
    Active Awards
    12
    New Awards (TTM)
    6
    Avg Remaining Term
    6.2 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25726N0262Department of Veterans AffairsDepartment of Veterans Affairs$319293May 1, 2026
    36C25926N0080Department of Veterans AffairsDepartment of Veterans Affairs$243669Oct 1, 2025
    36C24826N0634Department of Veterans AffairsDepartment of Veterans Affairs$62668Jul 10, 2026
    36C25726N0313Department of Veterans AffairsDepartment of Veterans Affairs$27658Apr 3, 2026
    36C25726N0254Department of Veterans AffairsDepartment of Veterans Affairs$15965Jun 5, 2026
    36C25726N0052Department of Veterans AffairsDepartment of Veterans Affairs$0Jan 10, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    MDxHealth’s Revenue Growth Is Real, but the Margin Story Still Needs Work

    MDxHealth SA (NASDAQ: MDXH) reported a 16% year-over-year revenue increase in Q2 2026 to $27.2 million, indicating strong top-line growth. However, this growth was accompanied by a decline in gross margin, a wider operating loss, and negative adjusted EBITDA, primarily due to a shift towards lower-margin liquid-based diagnostics. The company is undergoing a strategic reset, focusing on prostate cancer diagnostics and integrating ExoDx, while exiting the Resolve UTI business.

    AlphaStreet•8/24/26•
    Neutral

    MDxHealth’s Revenue Growth Is Real, but the Margin Story Still Needs Work

    MDxHealth (NASDAQ: MDXH) reported a 16% year-over-year revenue increase in Q2 2026, reaching $27.2 million, driven by a rebound in tissue-based testing and the contribution of liquid-based testing from ExoDx. Despite this top-line growth, the company faced margin pressure, a wider operating loss, and negative adjusted EBITDA, primarily due to the shift towards lower-margin liquid-based diagnostics. MDxHealth completed a strategic reset, including winding down legacy operations, and has strengthened its balance sheet with a recent $20 million placement, allowing time to improve profitability and integrate ExoDx.

    AlphaStreet•8/24/26•
    Somewhat-Bearish

    BTIG cuts MDxHealth stock price target on higher share count

    BTIG has lowered its price target for MDxHealth (NASDAQ: MDXH) to $2.00 from $4.00, while maintaining a Buy rating, primarily due to an increased share count from a recent $20 million stock offering. The company recently surpassed revenue expectations in Q2 2026 with $27.2 million, but missed on EPS, reporting a loss of $0.18. MDxHealth also removed a $10.4 million recoupment claim related to its wound-down Resolve business from its books.

    Investing.com•8/21/26•
    Somewhat-Bearish

    BTIG cuts MDxHealth stock price target on higher share count

    BTIG has lowered its price target for MDxHealth SA (NASDAQ:MDXH) shares from $4.00 to $2.00, while maintaining a Buy rating. This adjustment follows the company's second-quarter results and a recent $20 million stock offering that increased the share count. MDxHealth also reported strong Q2 revenue growth, surpassed analyst expectations, and resolved a significant Medicare recoupment claim related to its discontinued Resolve business.

    Investing.com•8/21/26•
    Somewhat-Bearish

    MDxHealth (MDXH) Q2 2026 Earnings Call Transcript

    MDxHealth reported a strong Q2 2026, with revenue increasing 16% year over year to $27.2 million, driven by growth in prostate cancer diagnostics and a 14% sequential increase. The company successfully transitioned its sales force, discontinued the Resolve UTI business, and eliminated a $10.4 million contingent liability, strengthening its balance sheet with a $20 million financing. Management is confident in achieving its full-year revenue guidance of $110 million-$115 million and returning to positive adjusted EBITDA by the end of 2026.

    The Globe and Mail•8/21/26•
    Somewhat-Bullish

    Frequently Asked Questions About MDXH

    Does MDXH pay dividends?
    MDxHealth SA ADR (MDXH) does not currently pay a regular dividend.
    What is MDXH's market cap?
    MDxHealth SA ADR (MDXH) has a market capitalization of $68.77M with a current stock price of $0.72.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In